KR20070089996A - 세동맥의 구조 및 기능의 개선 방법 - Google Patents
세동맥의 구조 및 기능의 개선 방법 Download PDFInfo
- Publication number
- KR20070089996A KR20070089996A KR1020077015635A KR20077015635A KR20070089996A KR 20070089996 A KR20070089996 A KR 20070089996A KR 1020077015635 A KR1020077015635 A KR 1020077015635A KR 20077015635 A KR20077015635 A KR 20077015635A KR 20070089996 A KR20070089996 A KR 20070089996A
- Authority
- KR
- South Korea
- Prior art keywords
- peptides
- amino acids
- group
- administration
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000002565 arteriole Anatomy 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 56
- 210000001367 artery Anatomy 0.000 claims abstract description 31
- 210000004556 brain Anatomy 0.000 claims abstract description 28
- 230000001771 impaired effect Effects 0.000 claims abstract description 28
- 210000003734 kidney Anatomy 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 274
- 239000013543 active substance Substances 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 41
- 230000006870 function Effects 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 31
- 201000001320 Atherosclerosis Diseases 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 239000007928 intraperitoneal injection Substances 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 abstract description 5
- 230000008816 organ damage Effects 0.000 abstract description 5
- 235000001014 amino acid Nutrition 0.000 description 203
- 229940024606 amino acid Drugs 0.000 description 201
- 102000004196 processed proteins & peptides Human genes 0.000 description 188
- 150000001413 amino acids Chemical class 0.000 description 174
- 241000699670 Mus sp. Species 0.000 description 95
- -1 GP80 Proteins 0.000 description 82
- 125000006239 protecting group Chemical group 0.000 description 80
- 230000002209 hydrophobic effect Effects 0.000 description 76
- 102000015779 HDL Lipoproteins Human genes 0.000 description 46
- 108010010234 HDL Lipoproteins Proteins 0.000 description 46
- 230000002378 acidificating effect Effects 0.000 description 45
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 230000002950 deficient Effects 0.000 description 34
- 108010001831 LDL receptors Proteins 0.000 description 33
- 235000021068 Western diet Nutrition 0.000 description 31
- 230000003110 anti-inflammatory effect Effects 0.000 description 26
- 150000003904 phospholipids Chemical class 0.000 description 25
- 210000001627 cerebral artery Anatomy 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000002792 vascular Effects 0.000 description 19
- 108010007622 LDL Lipoproteins Proteins 0.000 description 18
- 102000007330 LDL Lipoproteins Human genes 0.000 description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 230000004087 circulation Effects 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 16
- 230000037213 diet Effects 0.000 description 16
- 102000007469 Actins Human genes 0.000 description 15
- 108010085238 Actins Proteins 0.000 description 15
- 108010016626 Dipeptides Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoyl phosphatidylcholine Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000002460 smooth muscle Anatomy 0.000 description 14
- 125000001931 aliphatic group Chemical group 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 150000008574 D-amino acids Chemical class 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 102000004895 Lipoproteins Human genes 0.000 description 9
- 108090001030 Lipoproteins Proteins 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 230000006886 spatial memory Effects 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 7
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 7
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 7
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 7
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 150000008575 L-amino acids Chemical class 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000003704 aspartic acid Nutrition 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 238000010647 peptide synthesis reaction Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000008719 thickening Effects 0.000 description 7
- 108090000197 Clusterin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 239000012062 aqueous buffer Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 239000010755 BS 2869 Class G Substances 0.000 description 5
- 102000003780 Clusterin Human genes 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 4
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000006410 Apoproteins Human genes 0.000 description 3
- 108010083590 Apoproteins Proteins 0.000 description 3
- 239000004821 Contact adhesive Substances 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004219 arterial function Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000001196 vasorelaxation Effects 0.000 description 3
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- CDZVJFRXJAUXPP-AREMUKBSSA-N 2-O-glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCC(O)=O)COP([O-])(=O)OCC[N+](C)(C)C CDZVJFRXJAUXPP-AREMUKBSSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 108010064945 D-4F peptide Proteins 0.000 description 2
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- NAACPBBQTFFYQB-XNTGVSEISA-N cholesteryl octadeca-9,12-dienoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC=CCC=CCCCCC)C1 NAACPBBQTFFYQB-XNTGVSEISA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003562 morphometric effect Effects 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 238000009377 nuclear transmutation Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HPYLHFWTUAGUNX-BGZSDMPXSA-N (3s)-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxo-3-[[(2s,6s)-2,6,10-triamino-4-[(diaminomethylideneamino)methyl]-5-oxodecanoyl]amino]butanoic acid Chemical compound NCCCC[C@H](N)C(=O)C(CN=C(N)N)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O HPYLHFWTUAGUNX-BGZSDMPXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- JDSRHVWSAMTSSN-IRQZEAMPSA-N 13(S)-HPODE Chemical compound CCCCC[C@H](OO)\C=C\C=C/CCCCCCCC(O)=O JDSRHVWSAMTSSN-IRQZEAMPSA-N 0.000 description 1
- BFWYTORDSFIVKP-VAEKSGALSA-N 15(S)-HPETE Chemical compound CCCCC[C@H](OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-VAEKSGALSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710126783 Acetyl-hydrolase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 244000064816 Brassica oleracea var. acephala Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102100032887 Clusterin Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108010079091 KRDS peptide Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GQUDMNDPQTXZRV-DCAQKATOSA-N Lys-Arg-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GQUDMNDPQTXZRV-DCAQKATOSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940123921 Nitric oxide synthase inhibitor Drugs 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000003615 TRPM2 Human genes 0.000 description 1
- 101150095096 TRPM2 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 210000005221 acidic domain Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229940092664 senior moment Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63431804P | 2004-12-06 | 2004-12-06 | |
| US60/634,318 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070089996A true KR20070089996A (ko) | 2007-09-04 |
Family
ID=36578567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077015635A Ceased KR20070089996A (ko) | 2004-12-06 | 2005-12-06 | 세동맥의 구조 및 기능의 개선 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7579319B2 (enExample) |
| EP (1) | EP1827472A4 (enExample) |
| JP (2) | JP2008522980A (enExample) |
| KR (1) | KR20070089996A (enExample) |
| CN (1) | CN101115496B (enExample) |
| AU (1) | AU2005314043A1 (enExample) |
| BR (1) | BRPI0517148A (enExample) |
| CA (1) | CA2595067A1 (enExample) |
| IL (1) | IL183689A (enExample) |
| MX (1) | MX2007006750A (enExample) |
| NO (1) | NO20073453L (enExample) |
| NZ (1) | NZ555826A (enExample) |
| RU (1) | RU2414236C2 (enExample) |
| WO (1) | WO2006063132A2 (enExample) |
| ZA (1) | ZA200705489B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| EP1599173B1 (en) * | 2002-11-13 | 2017-02-22 | The Uab Research Foundation | Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EA200900786A1 (ru) * | 2005-04-29 | 2009-10-30 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида |
| EP2049137A4 (en) | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| JP2010537638A (ja) * | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| US20130095122A1 (en) * | 2010-03-17 | 2013-04-18 | Anja Katrin Bosserhoff | Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein |
| CN104039810A (zh) | 2011-08-29 | 2014-09-10 | 加利福尼亚大学董事会 | 使用高密度脂蛋白(hdl)相关分子治疗和预防促炎性病状 |
| US9539300B2 (en) | 2012-03-31 | 2017-01-10 | The Regents Of The University Of California | Modulating disease through genetic engineering of plants |
| CN103740659B (zh) * | 2012-05-10 | 2015-06-03 | 江南大学 | 一种提高酶热稳定性的方法 |
| CN103740661B (zh) * | 2012-05-10 | 2015-06-03 | 江南大学 | 一种提高酶热稳定性的方法 |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| US10905736B2 (en) | 2016-09-28 | 2021-02-02 | The Regents Of The University Of California | Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism |
| DE102017114262A1 (de) | 2017-06-27 | 2018-12-27 | Salzgitter Flachstahl Gmbh | Stahllegierung mit verbesserter Korrisionsbeständigkeit bei Hochtemperaturbeanspruchung und Verfahren zur Herstellung von Stahlband aus dieser Stahllegierung |
| US11410246B2 (en) | 2019-06-06 | 2022-08-09 | Salus Finance, LLC | System and method for consolidation, reconciliation and payment management |
| CN115379847A (zh) * | 2020-04-15 | 2022-11-22 | 拉托科公司 | 用于调节代谢型谷氨酸受体5的合成肽 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3767040A (en) | 1971-03-01 | 1973-10-23 | Minnesota Mining & Mfg | Pressure-sensitive polyurethane adhesives |
| US4155913A (en) | 1973-02-08 | 1979-05-22 | Hoffmann-La Roche Inc. | Thienotriazolodiazepine derivatives |
| HU185263B (en) | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| CH661438A5 (it) | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| US4618600A (en) * | 1984-04-19 | 1986-10-21 | Biotechnology Research Associates, J.V. | Novel polypeptide diuretic/vasodilators |
| US5258368A (en) * | 1984-04-19 | 1993-11-02 | Scios Nova, Inc. | Atrial natriuretic/vasodilator peptide compounds |
| US5212286A (en) * | 1984-04-19 | 1993-05-18 | Scios Nova Inc. | Atrial natriuretic/vasodilator peptide compounds |
| US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| JPH022957Y2 (enExample) | 1985-01-28 | 1990-01-24 | ||
| NZ229004A (en) | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
| US5182261A (en) | 1989-07-13 | 1993-01-26 | The Rockefeller University | Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof |
| DE3933850A1 (de) | 1989-10-06 | 1991-04-18 | Schering Ag | Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins |
| US5480869A (en) * | 1990-01-09 | 1996-01-02 | The Regents Of The University Of California | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues |
| AU662885B2 (en) | 1990-06-07 | 1995-09-21 | Scripps Research Institute, The | APO AI polypeptides, antibodies, and immunoassays |
| DE4101895C1 (enExample) * | 1991-01-23 | 1991-12-05 | Forschungszentrum Juelich Gmbh, 5170 Juelich, De | |
| US5646119A (en) | 1991-11-01 | 1997-07-08 | Periodontix, Inc. | D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents |
| WO1993025581A1 (en) | 1992-06-12 | 1993-12-23 | N.V. Innogenetics S.A. | New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| US5344822A (en) | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
| WO1994004563A1 (fr) | 1992-08-14 | 1994-03-03 | Shino-Test Corporation | PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS |
| US5358934A (en) * | 1992-12-11 | 1994-10-25 | The United States Of America As Represented By The Secretary Of Agriculture | Materials and methods for control of pests |
| US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| EP0735893B1 (en) | 1993-09-14 | 2008-11-26 | Pharmexa Inc. | Pan dr-binding peptides for enhancement of the immune response |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| DE69423243T2 (de) * | 1994-05-12 | 2000-11-02 | Orsolya Csuka | Stoffe zur aufhebung von arzneimittelresistenzen |
| US5595973A (en) | 1994-09-12 | 1997-01-21 | Biomeasure Incorporated | Protection of hemopoietic cells during chemotherapy or radiotherapy |
| US6169073B1 (en) | 1995-02-16 | 2001-01-02 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| KR0152840B1 (ko) | 1995-05-16 | 1998-10-01 | 구자홍 | 전자레인지의 캐비티 구조 |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| FR2735131B1 (fr) | 1995-06-12 | 1997-08-22 | Rech De Pathologie Appliquee S | Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament |
| TR199800406T1 (en) | 1995-09-09 | 1998-05-21 | F.Hoffmann-La Roche Ag | Alipoprotein A-I d�zeylerinin artt�r�lmas� i�in bir tienotriazolodiazepinin kullan�lmas�. |
| US6277826B1 (en) * | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| CN1109047C (zh) | 1996-03-29 | 2003-05-21 | D·博菲利 | 作为胆固醇和其它脂类摄取抑制剂的两亲分子 |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| WO2001032837A1 (en) * | 1999-11-02 | 2001-05-10 | Human Genome Sciences, Inc. | 19 human secreted proteins |
| EP1003501B9 (en) * | 1997-04-02 | 2005-06-08 | The Brigham And Women's Hospital, Inc. | Use of an agent for lowering the risk of cardiovascular disease |
| US6696545B1 (en) | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| AU6877998A (en) * | 1997-04-11 | 1998-11-11 | Warner-Lambert Company | Dipeptide inhibitors of protein farnesyltransferase |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| DE69805697T3 (de) | 1997-04-24 | 2006-11-30 | Chemoxal S.A. | Desinfizierende und fungizide Zusammensetzung auf der Basis von Peressigsäure und einem Aminoxid |
| IN185761B (enExample) | 1997-05-13 | 2001-04-28 | Council Scient Ind Res | |
| US6635623B1 (en) | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| CA2301634A1 (en) | 1997-07-15 | 1999-01-28 | Pradeep Ghosh | Determining alcohol intake using sialic acid/apo j |
| AU8823498A (en) | 1997-07-31 | 1999-02-22 | American Home Products Corporation | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| HUP0004400A3 (en) | 1997-11-05 | 2002-10-28 | Novartis Ag | Dipeptide nitriles, process for their preparation, pharmaceutical compositions comprising thereof and their use |
| US6191151B1 (en) * | 1997-11-12 | 2001-02-20 | Howard M. Zik | Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers |
| US6320017B1 (en) * | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US20030077641A1 (en) | 1998-03-11 | 2003-04-24 | Laskowitz Daniel T. | Methods of suppressing microglial activation and systemic inflammatory responses |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| AU3356899A (en) | 1998-03-17 | 1999-10-11 | Uab Research Foundation, The | Synthetic peptides that enhance ldl uptake |
| US6846636B1 (en) * | 1998-05-15 | 2005-01-25 | American National Red Cross | Methods and compositions for HDL holoparticle uptake receptor |
| US6019739A (en) * | 1998-06-18 | 2000-02-01 | Baxter International Inc. | Minimally invasive valve annulus sizer |
| JP5101764B2 (ja) | 1998-07-30 | 2012-12-19 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | Ｈｉｖ膜融合のインヒビター |
| US6172071B1 (en) * | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| AU6411199A (en) * | 1998-10-13 | 2000-05-01 | Chiron Corporation | Angiogenically effective unit dose of fgf and method of administering |
| US6440934B1 (en) * | 1998-10-13 | 2002-08-27 | Chiron Corporation | Angiogenically effective unit dose of FGF-2 and method of use |
| US6228989B1 (en) * | 1998-11-13 | 2001-05-08 | The Regents Of The University Of California | Peptide substrates phosphorylated by P21-activated protein kinase |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US6332017B1 (en) | 1999-01-25 | 2001-12-18 | Vanderbilt University | System and method for producing pulsed monochromatic X-rays |
| US7544772B2 (en) | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| GB9911689D0 (en) | 1999-05-19 | 1999-07-21 | Medical Res Council | Refolding method |
| US6727063B1 (en) | 1999-09-10 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Single nucleotide polymorphisms in genes |
| GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| US20030040505A1 (en) | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US6596544B1 (en) | 2000-03-31 | 2003-07-22 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| CA2404350A1 (en) | 2000-03-31 | 2001-10-11 | The Regents Of The University Of California | Control of a gene induced by oxidized lipids in human artery wall cells |
| PT1290013E (pt) * | 2000-04-21 | 2006-06-30 | Amgen Inc | Derivados dos peptidos apo-ai/aii |
| US6444681B1 (en) * | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| US6610716B2 (en) * | 2000-07-13 | 2003-08-26 | Alteon Incorporated | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7166578B2 (en) * | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| EP1186299A1 (en) | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
| WO2002059077A1 (en) | 2001-01-26 | 2002-08-01 | Takeda Chemical Industries, Ltd. | Aminoethanol derivatives |
| JP2002226457A (ja) | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| US6815426B2 (en) * | 2001-02-16 | 2004-11-09 | E. I. Du Pont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| MXPA03009647A (es) * | 2001-04-19 | 2004-01-29 | Vertex Pharma | Heterociclildicarbamidas como inhibidores de caspasa. |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| EP1423137B1 (en) * | 2001-08-06 | 2009-04-29 | Cubist Pharmaceuticals, Inc. | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates |
| US7348206B2 (en) | 2001-10-26 | 2008-03-25 | The Regents Of The University Of California | Formation of self-assembled monolayers of redox SAMs on silicon for molecular memory applications |
| US20030125260A1 (en) | 2001-10-31 | 2003-07-03 | Fortuna Haviv | Tetra-and pentapeptides having antiangiogenic activity |
| US7308303B2 (en) * | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
| US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| AU2003202737A1 (en) | 2002-02-28 | 2003-09-09 | Koninklijke Philips Electronics N.V. | Method for controlling the mode of an electronic application |
| US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| CN101745112A (zh) * | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| AU2003291206A1 (en) | 2002-12-04 | 2004-06-23 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004069206A2 (en) | 2003-02-04 | 2004-08-19 | University Of Connecticut Health Center | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| US20050070996A1 (en) * | 2003-04-08 | 2005-03-31 | Dinh Thomas Q. | Drug-eluting stent for controlled drug delivery |
| US6936961B2 (en) | 2003-05-13 | 2005-08-30 | Eastman Kodak Company | Cascaded organic electroluminescent device having connecting units with N-type and P-type organic layers |
| US7291590B2 (en) | 2003-06-12 | 2007-11-06 | Queen's University At Kingston | Compositions and methods for treating atherosclerosis |
| ATE397016T1 (de) * | 2003-06-30 | 2008-06-15 | Univ Lausanne | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen |
| US7781219B2 (en) | 2003-12-05 | 2010-08-24 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| CA2577026A1 (en) | 2004-08-11 | 2006-02-23 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US20060205669A1 (en) | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| RU2414236C2 (ru) | 2004-12-06 | 2011-03-20 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Способ улучшения структуры и/или функций артериол |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EA200900786A1 (ru) | 2005-04-29 | 2009-10-30 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида |
| RU2007148927A (ru) | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
-
2005
- 2005-12-06 RU RU2007125589/15A patent/RU2414236C2/ru not_active IP Right Cessation
- 2005-12-06 CN CN2005800477560A patent/CN101115496B/zh not_active Expired - Fee Related
- 2005-12-06 AU AU2005314043A patent/AU2005314043A1/en not_active Abandoned
- 2005-12-06 KR KR1020077015635A patent/KR20070089996A/ko not_active Ceased
- 2005-12-06 NZ NZ555826A patent/NZ555826A/en not_active IP Right Cessation
- 2005-12-06 BR BRPI0517148-2A patent/BRPI0517148A/pt not_active IP Right Cessation
- 2005-12-06 JP JP2007544634A patent/JP2008522980A/ja active Pending
- 2005-12-06 CA CA002595067A patent/CA2595067A1/en not_active Abandoned
- 2005-12-06 MX MX2007006750A patent/MX2007006750A/es unknown
- 2005-12-06 EP EP05853364A patent/EP1827472A4/en not_active Withdrawn
- 2005-12-06 WO PCT/US2005/044422 patent/WO2006063132A2/en not_active Ceased
- 2005-12-06 US US11/296,582 patent/US7579319B2/en not_active Expired - Lifetime
-
2007
- 2007-06-05 IL IL183689A patent/IL183689A/en not_active IP Right Cessation
- 2007-07-04 NO NO20073453A patent/NO20073453L/no not_active Application Discontinuation
- 2007-07-05 ZA ZA200705489A patent/ZA200705489B/xx unknown
-
2009
- 2009-06-04 US US12/478,593 patent/US8236754B2/en not_active Expired - Fee Related
-
2012
- 2012-01-27 JP JP2012015784A patent/JP2012082232A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US7579319B2 (en) | 2009-08-25 |
| WO2006063132A3 (en) | 2006-08-17 |
| US8236754B2 (en) | 2012-08-07 |
| JP2008522980A (ja) | 2008-07-03 |
| CA2595067A1 (en) | 2006-06-15 |
| EP1827472A2 (en) | 2007-09-05 |
| NO20073453L (no) | 2007-08-28 |
| IL183689A0 (en) | 2007-09-20 |
| WO2006063132A2 (en) | 2006-06-15 |
| MX2007006750A (es) | 2007-11-23 |
| NZ555826A (en) | 2009-11-27 |
| EP1827472A4 (en) | 2012-09-05 |
| CN101115496A (zh) | 2008-01-30 |
| CN101115496B (zh) | 2012-03-07 |
| IL183689A (en) | 2010-12-30 |
| RU2007125589A (ru) | 2009-01-20 |
| US20060234908A1 (en) | 2006-10-19 |
| ZA200705489B (en) | 2008-09-25 |
| US20090286741A1 (en) | 2009-11-19 |
| RU2414236C2 (ru) | 2011-03-20 |
| BRPI0517148A (pt) | 2008-09-30 |
| AU2005314043A1 (en) | 2006-06-15 |
| JP2012082232A (ja) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8236754B2 (en) | Methods for improving the structure and function of arterioles | |
| US6664230B1 (en) | Orally administered peptides to ameliorate atherosclerosis | |
| JP4361809B2 (ja) | アテローム性硬化症を改善するｇ−タイプペプチド | |
| AU2001286732A1 (en) | Orally administered peptides to ameliorate atherosclerosis | |
| NZ580650A (en) | Methods for improving the structure and function of arterioles | |
| AU2007237157B2 (en) | Peptides that ameliorate atherosclerosis | |
| HK1110011B (en) | Orally administered peptides to ameliorate atherosclerosis | |
| HK1055400B (en) | Orally administered peptides to ameliorate atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070706 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20101206 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120920 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130326 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20120920 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |